Praxis Precision Medicines (NASDAQ:PRAX) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Praxis Precision Medicines logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • JPMorgan raised its price target on Praxis Precision Medicines to $725 from $700 and maintained an “overweight” rating, implying 136.66% upside from the share price cited in the report.
  • Analyst views are mixed: the stock has a “Moderate Buy” consensus and an average target of $660.50, with targets ranging from $189 to $1,050.
  • PRAX shares fell 1.5% Friday to $306.34. The company reported quarterly EPS of -$3.23, beating analyst estimates of -$3.54.
  • MarketBeat previews top five stocks to own in December.

Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) had its target price upped by equities research analysts at JPMorgan Chase & Co. from $700.00 to $725.00 in a report issued on Friday, Benzinga reports. The brokerage currently has an "overweight" rating on the stock. JPMorgan Chase & Co.'s target price suggests a potential upside of 136.66% from the company's current price.

Several other brokerages have also weighed in on PRAX. Guggenheim raised their price objective on shares of Praxis Precision Medicines from $800.00 to $1,050.00 and gave the stock a "buy" rating in a report on Monday. Wedbush lifted their price target on Praxis Precision Medicines from $188.00 to $189.00 and gave the stock an "underperform" rating in a research note on Tuesday, November 10th. Royal Bank Of Canada boosted their price objective on Praxis Precision Medicines from $462.00 to $478.00 and gave the company an "outperform" rating in a report on Tuesday, November 10th. BTIG Research restated a "buy" rating and set a $826.00 price objective on shares of Praxis Precision Medicines in a research note on Monday, November 9th. Finally, The Goldman Sachs Group reaffirmed a "buy" rating and set a $575.00 target price (up from $470.00) on shares of Praxis Precision Medicines in a report on Friday, August 21st. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Praxis Precision Medicines has an average rating of "Moderate Buy" and a consensus price target of $660.50.

Check Out Our Latest Stock Report on PRAX

Praxis Precision Medicines Stock Down 1.5%

Shares of PRAX traded down $4.56 during trading on Friday, reaching $306.34. The company's stock had a trading volume of 336,088 shares, compared to its average volume of 472,468. Praxis Precision Medicines has a twelve month low of $160.11 and a twelve month high of $392.70. The company has a market cap of $8.56 billion, a price-to-earnings ratio of -23.92 and a beta of 2.85. The company has a fifty day moving average of $286.77 and a two-hundred day moving average of $314.30.

Praxis Precision Medicines (NASDAQ:PRAX - Get Free Report) last issued its quarterly earnings results on Monday, November 9th. The company reported ($3.23) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($3.54) by $0.31. As a group, equities analysts forecast that Praxis Precision Medicines will post -13.72 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC increased its stake in shares of Praxis Precision Medicines by 6.8% in the first quarter. Janus Henderson Group PLC now owns 3,458,863 shares of the company's stock valued at $1,113,514,000 after purchasing an additional 218,777 shares during the period. Perceptive Advisors LLC raised its holdings in shares of Praxis Precision Medicines by 2.0% in the 1st quarter. Perceptive Advisors LLC now owns 2,035,986 shares of the company's stock worth $655,974,000 after purchasing an additional 40,000 shares in the last quarter. Bank of America Corp DE lifted its position in shares of Praxis Precision Medicines by 2.3% during the 1st quarter. Bank of America Corp DE now owns 534,604 shares of the company's stock valued at $172,244,000 after acquiring an additional 11,841 shares during the last quarter. Logos Global Management LP boosted its position in shares of Praxis Precision Medicines by 63.5% in the 3rd quarter. Logos Global Management LP now owns 425,000 shares of the company's stock valued at $123,773,000 after purchasing an additional 165,000 shares during the period. Finally, Vivo Capital LLC raised its holdings in Praxis Precision Medicines by 3.0% during the 1st quarter. Vivo Capital LLC now owns 338,895 shares of the company's stock worth $109,189,000 after buying an additional 10,000 shares during the period. Institutional investors and hedge funds own 67.84% of the company's stock.

About Praxis Precision Medicines

(Get Free Report)

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on developing treatments for neurological and psychiatric disorders. The company applies neuroscience and precision-medicine research to conditions involving abnormalities in brain circuits and neuronal activity. Its investigational programs have included small-molecule therapies for disorders such as essential tremor and epilepsy, as well as genetic-medicine approaches for certain rare neurological conditions. These candidates are in development and are not approved treatments.

Recommended Stories

Analyst Recommendations for Praxis Precision Medicines (NASDAQ:PRAX)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Praxis Precision Medicines Right Now?

Before you consider Praxis Precision Medicines, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Praxis Precision Medicines wasn't on the list.

While Praxis Precision Medicines currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines